GlassScriptPhysician profile
David Marcos Bowen
NPI 1972990976
$47,255.97
in general payments reported to CMS, 2019-2025
23 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $894 · 2021: $1,925 · 2022: $1,861 · 2023: $1,813 · 2024: $3,062 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $6,163 · Food and Beverage: $6,092 · Travel and Lodging: $3,309 · Entertainment: $23.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,662.50 |
| Consulting Fee | $6,162.50 |
| Food and Beverage | $6,092.34 |
| Travel and Lodging | $3,308.80 |
| Entertainment | $23.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $34,383.21 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Abbott Laboratories | $7,007.64 | 2019-2025 | Eterna, Proclaim |
| Stryker Corporation | $1,703.52 | 2025 | Augment Injectable, Mild Device Kit, Optablate |
| Spinal Simplicity, LLC | $870.45 | 2020-2025 | Ha Minuteman G3-R |
| Nalu Medical, INC. | $848.88 | 2024 | Nalu Neurostimulation System |
| Nevro Corp. | $540.95 | 2019-2024 | Senza |
| Abbvie INC. | $402.51 | 2021-2025 | Botox |
| Globus Medical, INC. | $232.34 | 2025 | Vyrsa V1, Senza |
| Medtronic, INC. | $212.27 | 2022-2024 | Intellis Adaptivestim |
| Relievant Medsystems, INC. | $173.14 | 2022 | |
| Foundation Fusion Solutions, LLC | $171.66 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.35 | 2023-2025 | Relistor |
| Saluda Medical Americas, INC. | $100.72 | 2023-2024 | Evoke Scs, Evoke |
| Bioventus LLC | $97.53 | 2023-2024 | Durolane, Durolane |
| Vertex Pharmaceuticals Incorporated | $87.31 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $84.16 | 2020-2021 | |
| Vertos Medical, INC. | $79.69 | 2022 | |
| Almatica Pharma LLC | $24.79 | 2023 | Gralise |
| Curonix LLC | $23.43 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pacira Pharmaceuticals Incorporated | $22.39 | 2023 | Zilretta, Iovera, Exparel |
| Biohaven Pharmaceutical Holding Company LTD. | $18.09 | 2022 | |
| Depuy Synthes Sales INC. | $17.22 | 2025 | Monovisc, Orthovisc |
| Ferring Pharmaceuticals INC. | $14.72 | 2023 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.